Shingrix is a recombinant, adjuvanted vaccine designed to prevent shingles (herpes zoster) and its complications, including postherpetic neuralgia, in adults aged 50 years and older and in adults aged 19 years and older who are or will be immunocompromised. It is the preferred shingles vaccine recommended by health authorities in many countries, widely used since the early 2020s, and formulated to provide strong, long-lasting protection with a two-dose series. The following explains what Shingrix is, how it works, who should receive it, expected side effects, dosing schedule, and practical considerations for use.
What is Shingrix and how it works
Shingrix is a non-live, recombinant subunit vaccine that uses a virus-like particle made from the glycoprotein E (gE) of varicella-zoster virus combined with a proprietary adjuvant (AS01B). The gE antigen prompts the immune system to recognize the virus, while the adjuvant enhances and broadens the immune response. This design helps the vaccine maintain high effectiveness even as the immune system ages. Because Shingrix is non-live, it generally carries fewer contraindications than live-attenuated vaccines, though it may be associated with more common local and systemic reactions shortly after vaccination.
Who should get Shingrix
In most national guidance, Shingrix is recommended for:
- Adults 50 years of age and older, regardless of prior shingles, previous zoster vaccination with Zostavax (if received), or presumed past chickenpox infection.
- Adults aged 19 years and older who are or will be immunocompromised due to disease or therapy, with attention to timing relative to immunosuppressive conditions or medications.
Health care providers should evaluate individual medical history and timing of immunosuppression; guidance can vary by country and updated recommendations may emerge from authorities such as the CDC and ACIP, ECDC, and national immunization technical advisory groups.
Effectiveness and real-world evidence
Clinical trials and post-licensure data show that Shingrix is highly effective at preventing shingles and postherpetic neuralgia across a wide age range. Protection remains substantial years after completion of the series, though gradually waning over time is expected for many vaccines. Effectiveness can be influenced by age, time since vaccination, immunocompetence, and emerging zoster strain variants, with continued monitoring informing potential future booster or catch-up strategies.
Key effectiveness attributes (indicative ranges from pivotal trials)
| Metric | Approximate value | Context |
|---|---|---|
| Overall efficacy against shingles | >90% | Across immunocompetent adults in trials |
| Efficacy against postherpetic neuralgia | >85% | In adults 50 and older |
| Protection waning notable after | Years 3–5+ | Observed in long-term follow-up; varies by age |
| Effectiveness in immunocompromised | Lower but still substantial | Guiding use in specific groups under medical supervision |
Dosing schedule and timing
Shingrix is administered as a two-dose series. The second dose is typically given 2 to 6 months after the first dose, and either interval within that range is considered acceptable. People who have previously received Zostavax should wait at least 8 weeks before receiving the first dose of Shingrix. Individuals who have had recent or current shingles may be advised to wait until the acute episode has largely resolved, though guidance on timing can differ. Missed or delayed doses do not require restarting the series; additional doses beyond two are not recommended in standard use.
Common side effects and management
Most people experience some side effects, which are usually mild to moderate and resolve within a few days. Local reactions such as pain, erythema, and swelling at the injection site are common. Systemic reactions such as fatigue, headache, myalgia, fever, and gastrointestinal symptoms also occur. These responses are primarily due to the strong immune activation from the adjuvant and do not generally indicate a serious problem. Strategies such as rest, hydration, cool compresses, and use of antipyretics or analgesics (as advised by a clinician) can help manage symptoms. Severe allergic reactions are rare but should be evaluated promptly.
Contraindications, precautions, and special populations
Shingrix is generally contraindicated following a prior severe allergic reaction to a vaccine component. Precautions include careful evaluation for immunocompromise and planning timing of vaccination relative to immunosuppressive therapies. Pregnancy and lactation are not absolute contraindications in many guidance documents, but consultation with a clinician is advised. Use in acute, moderate, or severe acute illness is commonly deferred until recovery. Decisions in complex clinical scenarios should be individualized with input from a health care provider and consideration of local guidance.
Practical considerations and counseling points
When discussing Shingrix with patients, emphasize that it is non-live and suitable for many immunocompromised individuals, that two doses are needed for optimal protection, and that common reactions are expected signs of immune activation. Encourage reporting persistent or concerning symptoms to their clinician and remind patients that continuing healthy habits and recommended screenings remain important even after vaccination. Providers should document the vaccine product, lot number, and date, and report vaccinations to immunization registries per local requirements, which supports population-level monitoring and recall functions.